Hepatitis B virus (HBV) genotype F1b infection is strongly associated with hepatocellular carcinoma (HCC) in young
H epatocellular carcinoma (HCC) is the fifth most common cancer worldwide, and more than 686,000 deaths every year are attributed to complications of hepatitis B virus (HBV) infection, including cirrhosis and HCC.
(1) The prevalence of HBV infection is closely correlated with the incidence of HCC, which varies widely around the world. (2) HBV is categorized into nine genotypes with distinct geographic distributions, (3) based 20 on nucleotide differences of >8%. Genetic diversity and viral mutations contribute to their pathogenic properties and the clinical outcomes of HBV infection. (4) (5) (6) Cumulative studies indicate that genotype C infection is a high-risk factor for HCC development, greater than other genotypes in chronic hepatitis B patients. (7, 8) In Asia, where genotypes B and C are predominant, the presence of A1762T/G1764A mutations in the basal core promoter (BCP) significantly and independently increases the risk of HCC development in patients chronically infected with HBV genotype C. (9, 10) We have compared the pathogenic effects of various HBV genotypes and specific mutations and found that genotype C2 induced liver fibrosis resulting from oxidative stress damage, while genotype A2 and B1 infections resulted in relatively less hepatic damage. (11, 12) These clinical and experimental data suggest that HBV genotypes and mutations could contribute to progressive liver diseases.
Among the overall burden of chronic HBV in the United States, Alaskan Native (AN) people have the highest HBV seroprevalence, 3.1% versus 0.27% in the remaining population. (13, 14) Furthermore, in a study of chronic carriers of HBV among AN people in 1990, the annual incidence rate of HCC was 387/100,000 for men and 63/100,000 for women, (15) whereas the worldwide age-adjusted incidence was 14.67/100,000 for men and 4.92/100,000 for women. (16) Chronic HBV infection in AN people is caused by five genotypes, A2, B6, C2, D, and F1, with prevalence rates of 12.6%, 3.9%, 6.8%, 56.6%, and 20.1%, respectively. In a nested case-control study that followed a cohort of 1,176 AN people with chronic HBV infection for 20 years, genotype F1 infection accounted for 68% of HCC patients, and the median age at HCC diagnosis of genotype F1-infected patients was lower than that of those with genotypes A2, B6, C2, and D infections (22.5 versus 60 years, respectively; P = 0.002). (17, 18) However, the numbers of BCP and precore (PC) mutations were not associated with HCC compared with genotype F1 without HCC at diagnosis, (18) suggesting that HCC development with genotype F1 infection might be associated with mutations other than the HCC-associated mutations reported in other genotypes.
In this study, we show that the accumulation of core mutations, T1938C (V13A) and A2051C (N51H), is associated with HCC development in AN people with HBV genotype F1b. Furthermore, we provide evidence that A2051C (N51H) enhances viral replication in vitro and in vivo, which was associated with increased stability of core protein dimerization. In chimeric mice with human hepatocytes, the A2051C mutation, in combination with BCP and PC mutations, accelerates disease progression in association with up-regulation of five genes, v-myc avian myelocytomatosis viral oncogene homolog (MYC), Grb2-associated binding protein 2 (GAB2), bradykinin receptor B2 (BDKRB2), follistatin (FST), and mitogen-activated protein kinase kinase kinase 8 (MAP3K8). These genes have been associated with cell proliferation and HCC development.
Patients and Methods

sUBJeCts
Details of the study cohort have been described. (18, 19) In brief, the study cohort consisted of 1,536 ANs with chronic HBV infection under semiannual surveillance for HCC. HCC was diagnosed by abdominal ultrasound, liver biopsy, and computed tomographic scans and biochemically by measuring alpha-fetoprotein levels. Of the total of 52 HCC patients, 32 were infected with HBV genotype F1b. Subjects were excluded if their follow-up sample was not available in an amount adequate for extraction of HBV DNA (n = 3), if PCR failed because of a low quantity of DNA (below about 1,000 copies/mL, the detection limit of our nested PCR assay) (n = 6), or other specimens were inadequate (n = 3) (Supporting Fig. S1 ). Long-term serial serum samples, each including three points (entry approximately 13 years prior to HCC diagnosis, 4-7 years prior to HCC diagnosis, HCC diagnosis) from 20 HCC patients with HBV genotype F1 were provided from the Alaska Areas Native Health Services/Arctic Investigations Program of the Centers for Disease Control and Prevention serum bank in Anchorage. Written informed consent was obtained from each patient, and the study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Alaska area institutional review board (2001-07-022 and 1996-01-001), the Alaska Native Tribal Health Consortium, and The Southcentral Foundation board of directors. Ethical approval was also obtained from the human institutional review board of Nagoya City University Graduate School of Medical Sciences (2005-217).
aNalysis oF ViRologiCal MaRKeRs
HBV DNA was extracted from 200 μL of patients' serum using the Roche High Pure Viral Nucleic Acid Kit (Roche Diagnostics). A real-time PCR assay (TaqMan) was used for DNA quantification. Hepatitis B e antigen (HBeAg) and antibody to HBeAg were determined by enzyme-linked immunosorbent assay, as described. (20) HBV DNA titers of chimeric mice were measured by real-time PCR, as described. (21) Hepatitis B surface antigen (HBsAg) was measured by a chemiluminescent enzyme immunoassay using a commercial kit (Fujirebio Inc., Tokyo, Japan), as described. (12, 22) seQUeNCiNg aND pHylogeNetiC aNalysis HBV complete or partial genomes from the isolates were sequenced as described. (23) Genetic distances were estimated by the six-parameter method, and phylogenetic trees were constructed with the neighbor-joining method, as described. (24) The reference sequences for phylogenetic analysis were retrieved from DDBJ/EMBL/GenBank. (25) More detailed procedures are given in the Supporting Information.
plasMiD CoNstRUCtioN FoR tHe HBV RepliCatioN MoDel
A plasmid carrying a replication-competent 1.24-fold HBV genotype F1b DNA genome, isolated from an HCC patient and with BCP and T1938C mutations, was used as the backbone construct for inserting or deleting the various mutations characterized in this study. The specific mutations A1762T/G1764A, G1896A, T1938C, and A2051C identified in the HCC group were inserted or deleted by site-directed mutagenesis, using first and second primer sets. More detailed procedures are given in the Supporting Information.
IN VITRO HBV RepliCatioN eFFiCaCy test
Huh-7 cells were transfected as described. (12, 26) Seventy-two hours later, the transfected cells were harvested to extract capsid-associated HBV DNA, HBV RNA, and total HBV RNA. HBV DNA and total HBV RNA contents were analyzed by Southern/ northern hybridization, as described. (12) Capsidassociated HBV RNA contents were quantified by real-time RT-PCR, as described. (27) More detailed procedures are given in the Supporting Information.
IN VITRO aNalysis oF CoRe pRoteiN DiMeRiZatioN staBility
HeLa cells were transfected with a plasmid carrying a competent hepatitis B core (HBc) protein capsid assembly domain fused to the Split-Gaussia princeps luciferase. (28) The luciferase activity in the supernatant was assayed to measure dimerization of the core protein. More detailed procedures are given in the Supporting Information.
IN VIVO iNFeCtiVity testiNg oF tHe HCC-assoCiateD MUtaNt UsiNg CHiMeRiC MiCe
Severe combined immunodeficiency mice carrying a transgene expressing a urokinase-type plasminogen activator gene and whose livers were replaced by human hepatocytes were infected with HBV genotype F1b wild-type strain; BCP/PC, BCP/PC/1938, or BCP/ PC/2051 mutant; or genotype Ce and Ae wild-type clones. (12, 27) Liver tissues were stained with hematoxylin and eosin, Masson's trichrome, or anti-STEM121 antibody or anti-cytokeratin 18 antibody as human specific antibodies and observed by fluorescence microscopy (Axio Observer.Z1; Zeiss). More detailed procedures are given in the Supporting Information.
IN VITRO iNFeCtioUs aBility testiNg oF HCC-assoCiateD MUtaNt UsiNg pRiMaRy HUMaN HepatoCytes
Primary human hepatocytes (PHHs) were infected with F wild-type or BCP/PC/2051 mutant at 5 genome equivalents/cell. To exclude the HBV attachment to the PHHs, neutral experiments using 1,000 mIU/mL of hepatitis B immunoglobulin (HBIG) were conducted in the culture medium after day 12 postinfection. HBV infectivity for each clone was determined from the HBV DNA and HBsAg levels in the supernatants and PHHs. HBsAg in the cells was stained with a goat monoclonal antibody to HBsAg (bs-1557G; Bioss, MA). Nuclei were stained with Hoechst 33342 (Dojindo, Japan). Signals were observed using In Cell Analyzer 2000 (GE Healthcare UK). More detailed procedures are given in the Supporting Information.
QUaNtitatiVe pCR
Total RNAs isolated from liver tissues of chimeric mice consisting of noninfected controls and HBV infection were used as templates for complementary DNA (cDNA) synthesis using the High-Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific, Waltham, MA). Target cDNAs were amplified by realtime detection PCR (Applied Biosystems). Specificity of the amplification products was normalized using human-specific hypoxanthine phosphoribosyl transferase 1. More detailed procedures are given in the Supporting Information.
MiCRoaRRay aNalysis
Total RNA was extracted from the liver tissues of chimeric mice consisting of noninfected controls and HBV infection with genotype F1b using the Qiagen RNeasy Mini kit (Qiagen, Valencia, CA). Gene expression profiles were obtained and compared in each group among control, F wild-type, BCP/PC/1938, and BCP/PC/2051 infection using GeneSpring GX (Agilent Technologies). More detailed procedures are given in the Supporting Information.
statistiCal aNalysis
All statistical values were compared by the χ 2 test with the Yates correction, Mann-Whitney U test, independent Student t tests, paired t test, unpaired t test, or one-way analysis of variance (ANOVA) tests. More detailed analyses are described in the legends of the figures and tables.
Results
CliNiCal aND ViRologiCal CHaRaCteRistiCs oF HCC patieNts WitH geNotype F1B
Longitudinal features of 20 HCC patients with chronic hepatitis B are shown in Table 1 . The median age of the HCC patients was 22.5 years (range 7-65, mean age 29.5 ± 19.0) at HCC diagnosis (Table 1) . A molecular evolutionary analysis showed that all strains from AN people belong to genotype F1b (Fig. 1) . In this cohort, we found core T1938C (V13A) and A2051C (N51H) mutations in the genotype F1b strains (Table 1) . Interestingly, these core T1938C and A2051C mutations were identified in genotype F1b of Alaska but not of South America, including Argentina, Chile, Peru, and Venezuela (Supporting Fig. S2 ), indicating that these core mutations are Alaska-specific. The Alaska-specific core mutations and BCP (A1762T/G1764A)/PC (G1896A) mutations had accumulated to a significantly greater extent by the time of HCC diagnosis. These mutations were rare among HCC patients at entry to the study but had accumulated during the follow-up of approximately 13 years. Some of the HCC patients already had significant accumulations of the core mutations and BCP mutations 4-7 years prior to HCC diagnosis (Table 1) . Complete HBV genome analysis did not reveal additional significant changes (data not shown). HBV DNA levels and HBeAg positivity rates had decreased significantly by the time of diagnosis (Table 1) .
seQUeNCe eVolUtioN oF tHe BCp, pC, aND CoRe RegioNs iN HCC patieNts
To determine whether the core T1938C and A2051C mutations have any relationship with the BCP/PC mutations that have been associated with HCC development, we examined how the proportion of patients with core mutations in combination with BCP and/or PC mutations changed during the follow-up of HCC patients ( Fig. 2A,B) . Dynamic changes of HBV mutation patterns were found in the HCC group as follows: 85% of HCC patients were infected with the wild-type strain, but only 10% had BCP mutations at entry ( Fig. 2A) . At the time of HCC diagnosis, 80% of HCC patients had developed BCP mutations (P < 0.0001; Fig. 2A and Table 1) , and in 65% of the patients these BCP mutations were in combination with the core T1938C and/or A2051C mutations (P < 0.01; Fig. 2A and Table 1) .
Interestingly, the Alaska-specific core mutations, T1938C and A2051C, mostly occurred in combination with BCP and/or PC mutations in HCC patients. Therefore, the combination of these core T1938C and A2051C mutations was subdivided in Fig. 2B . Despite there being no HCC patients with core mutations at entry, the percentage of T1938C and A2051C mutations with BCP and/or PC mutations had increased to 60% (P < 0.0001) and 25% (P < 0.05), respectively, at the time of HCC diagnosis ( Fig. 2B and domain (residues 1-144) and the C-terminal RNA/ DNA-binding domain (residues 145-183). Through the assembly domain, HBc forms stable dimers, which are the building blocks of the icosahedral nucleocapsid structure. (29) To examine the virological characteristics of the T1938C and A2051C Fig. 1 . Phylogenetic analysis of HBV isolates from HCC patients. The phylogenetic tree was constructed using the core region sequences of HBV isolates from 20 HCC patients, along with reference sequences derived from GenBank (denoted by accession numbers).
mutations, these were inserted by site-directed mutagenesis into a replication-competent, 1.24-fold length HBV genotype F1b clone isolated from an HCC patient. BCP and PC mutations that were also found in the HCC patients were inserted in combination with the core mutations. This yielded eight different clones, designated F wild-type, BCP (A1762T/G1764A), BCP/1938 (A1762T/ G1764A and T1938C), BCP/PC (A1762T/ G1764A and G1896A), BCP/PC/1938 (A1762T/ G1764A, G1896A and T1938C), BCP/PC/2051 (A1762T/G1764A, G1896A and A2051C), BCP/ PC/1938/2051 (A1762T/G1764A, G1896A, T1938C and A2051C), and 2051 (A2051C). To determine the replicative efficiency of these clones, we transiently transfected the constructs into Huh-7 cells and tested for HBV replication and transcription levels by Southern and northern blotting, respectively (Fig. 3A,B) . When the replication efficacy of these clones was compared with the wild-type strain (Fig. 3A) , the presence of the well-known BCP mutations (BCP, BCP/1938, BCP/PC, and BCP/ PC/1938) only moderately increased replication capacity (1.8-fold, 1.2-fold, 1.7-fold, and 1.5-fold changes of F wild-type, respectively). Interestingly, clones containing the 2051 mutation in the core region (BCP/PC/2051, BCP/PC/1938/2051, and 2051) replicated more efficiently than the F wild type (4.3-fold, 3.0-fold, and 3.6-fold changes relative to the F wild-type, respectively; P < 0.01). Although there was no commensurate increase in total pregenomic RNA expression, the amount of encapsidated pregenomic RNA was significantly increased by the A2051C mutation (P < 0.01; Fig.  3B ; Supporting Fig. S3) , suggesting that the presence of the A2051C mutation was sufficient to increase HBV replication at the posttranscriptional level.
Because T1938C (V13A) and A2051C (N51H) mutations are located in the capsid assembly domain, we hypothesized that these mutations enhanced replication through core stabilization, which in turn facilitates nucleocapsid formation. To test this, we used a split luciferase complementation assay, in which luciferase signal can be enhanced when core dimerization occurs ( Fig. 4A ; see Supporting Information for more detailed procedures). The clone containing the A2051C mutation (2051 [N51H]) exhibited significantly more luciferase activity than the F wild-type (4.0-fold greater than the F wild type, P < 0.01) and 1938 (V13A) mutation (3.6-fold greater than the 1938 [V13A] mutation, P < 0.01) (Fig. 4B) . These results indicated that the core A2051C mutation enhances HBV replication by facilitating core protein dimerization, although it is theoretically possible that the A2051C mutation affects the protein stability of HBc.
tHe BCp/pC/2051 MUtaNt CaN eNHaNCe tHe HBV iNFeCtioUs aBility iN CHiMeRiC MiCe
To investigate the infectivity and pathogenic potential of these genotype F1b mutants that exhibit a higher replication capacity than wild-type, we inoculated two groups of two to four chimeric mice with the infectious sources of the wild-type and BCP/PC/2051 mutants. Serum HBV DNA levels in the BCP/PC/2051 mutant-infected chimeric mice had increased significantly and ranged between 3.3 × 10 6 and 9.5 × 10 7 copies/mL on day 56 after inoculation, while those in the mice inoculated with F wild-type ranged between 1.2 and 3.4 × 10 4 copies/mL (Fig. 5) . Therefore, mice of the wild-type group with low infection were boosted with F wildtype HBV into the vein on days 63 and 64. Seventyseven days after HBV inoculation, the HBV DNA levels and HBsAg levels had increased significantly in the BCP/PC/2051 group, reaching 1.2 to 3.7 × 10 8 copies/mL and 2.8 to 8.4 × 10 4 IU/mL, respectively, while HBV DNA and HBsAg levels in mice infected with F wild-type were still approximately 100 times lower than those in the BCP/PC/2051 group at day 140 after infection ( Fig. 5A,B) . In an additional study, the mice inoculated with BCP/PC (n = 3) or BCP/PC/1938 (n = 4) mutant initially did not show viremia, suggesting low infectivity of these clones. After the booster inoculation on days 45 and 46, however, HBV DNA reached levels similar to BCP/PC/2051 (Supporting Fig. S4 ). Because the serum human albumin levels were comparable between these groups, the human hepatocyte reconstitution efficiency was similar in them (Supporting Figs. S5 and S6) . Collectively, these results suggest that the HCC-associated BCP/PC/2051 mutations enhance the HBV infectious ability in the in vivo HBV infection model. 
CoRe 2051 (N51H) iNCReases iNFeCtiVity By eNHaNCiNg HBV RepliCatioN iN pHHs
To confirm more precisely that HBV with the core 2051 (N51H) mutation with BCP and PC mutations has enhanced infectivity, we inoculated the same amount of wild-type or BCP/PC/2051 mutant HBV DNA into PHHs. Extracellular and intracellular HBsAg levels were similar between PHHs infected with the BCP/PC/2051 mutant and F wild-type at day 12 (Fig. 6B,C) , indicating that these clones infect PHHs with similar efficiency. In contrast, the extracellular HBV DNA levels of BCP/PC/2051-infected PHHs were already higher than those of wild-type at day 7 (P < 0.001; Fig.  6A ), presumably reflecting higher HBV DNA replication efficacy of BCP/PC/2051 mutant, as shown with Huh-7 cells in Fig. 3A . At day 22, the extracellular HBsAg levels were significantly higher in PHHs with the BCP/PC/2051 mutant than the wild-type (P < 0.001; Fig. 6B ). In addition, the frequency of HBsAg-positive cells and the amount of HBV DNA content were apparently higher in BCP/PC/2051-infected PHHs than wild typeinfected controls (Fig. 6C,D) . These differences probably reflected more efficient viral spread and replication of BCP/PC/2051 mutant than wild type. To test this notion, we added HBIG, which inhibits viral spread, to the culture medium from day 12 after inoculation. The intracellular HBsAg levels of the BCP/PC/2051 mutant at day 37 were significantly reduced by HBIG (Supporting Fig. S7A) . Furthermore, the intracellular HBV DNA levels at day 37 in the PHHs with the BCP/PC/2051 mutant, but not the wild-type, were clearly suppressed by HBIG (Supporting Fig. S7B ). These data suggest that the HCC-associated core 2051 (N51H) mutation with the BCP and PC mutations enhanced the infectious ability of genotype F1b.
tHe BCp/pC/2051 MUtaNt CaUses FiBRosis aND iNFlaMMatioN iN CHiMeRiC MiCe aND Up-RegUlates HCCassoCiateD geNe eXpRessioN
To investigate the influence of enhanced replication of BCP/PC/2051 mutant on liver injury in chimeric mice, we examined the histological features of long-term infection at 140-147 days using Masson's trichrome staining and hematoxylin and eosin staining. BCP/PC/2051 mutant-infected mice showed human hepatocytes with varying sizes of large nuclei, necrotic hepatocytes, and abundant neutrophil liver infiltration with hematoxylin and eosin stain (arrows) at day 147 (Fig. 7A) . In addition, strong bridging fibrosis (stage 2-3) was observed with Masson's trichrome stain (arrows). In contrast, mice infected with the wild-type strain showed only mild inflammation with no or minimal fibrosis at day 140 after infection. Importantly, the fibrosis observed in the BCP/ PC/2051 mutant-infected mice was restricted to the region of human hepatocytes but not mouse hepatocytes (Supporting Fig. S8 ). These data suggest that the BCP/PC/2051 mutant plays a critical role in HBVinduced liver injury in association with increased viral replication.
To evaluate further the pathogenesis of HBV BCP/PC/2051 mutant, we compared the gene expression levels and biological pathways in hepatocytes by microarray analysis between three groups of chimeric mice comprising five control mice (i.e., without infection, sacrificed at day 148-155), three F wild type-infected mice (sacrificed at day 140), and two BCP/PC/2051-infected mice (sacrificed at day 139-147). Compared to F wild-type strain and control mice, 126 genes were up-regulated >2.0-fold in the liver infected with the BCP/PC/2051 mutant ( Fig. 7B ; Supporting Table S1 ). Based on the 126 Fig. 5 . Transmission of core A2051C with BCP and PC mutations to chimeric mice. Groups of two or three chimeric mice were inoculated with HBV F1b wild-type strain or BCP/ PC/2051 mutant. (A) Serum HBV DNA levels and (B) HBsAg levels in the F wild-type group and BCP/PC/2051 group with long-term infection. Statistical significance was established by unpaired Student t testing; *P < 0.01 and **P < 0.05. Shaded areas represent HBV DNA levels and HBsAg levels below the detection limit (<10 4 copies/mL and <10 -1.7 IU/mL, respectively).
up-regulated genes, we found that 56 pathways were significantly affected by BCP/PC/2051 infection (P < 0.05) (Supporting Table S2 ). Interestingly, MYC, GAB2, BDKRB2, FST, and MAP3K8 were included in more than five distinct pathways among the 56 pathways (Supporting Table S3 ) and could be associated with carcinogenesis or cell proliferation following viral infection (Supporting Table S4 ).
We then confirmed the mRNA expression levels of these five genes in mice infected with HBV genotype F1b wild-type strain and the BCP/PC/2051 mutant by real-time detection PCR and compared the gene expression levels with those in mice infected with genotypes Ae and Ce (Fig. 7C) . BCP/PC/2051 infection up-regulated the expression of MYC, GAB2, BDKRB2, FST, and MAP3K8 by 22.4-fold, 15.0-fold, 14.1-fold, 23.6-fold, and 5.8-fold relative to control, respectively, while F wild-type strain did so by 5.1-fold, 2.3-fold, 6.9-fold, 3.6-fold, and 2.6-fold relative to control, respectively. Interestingly, none of these genes were significantly up-regulated in mice infected with genotype Ae or Ce (Fig. 7C) , indicating that the up-regulation of these genes was genotype F1b-specific. Mice infected with the BCP/ PC or BCP/PC/1938 mutant showed only mild inflammation with no or minimal fibrosis at day 140 after infection, similar to mice infected with wildtype strain (Supporting Fig. S9A ). In chimeric mice infected with BCP/PC/1938 mutant, expression of BDKRB2 was significantly up-regulated as observed in the chimeric mice with the BCP/PC/2051 mutant (Supporting Fig. S9B ). However, expression of MYC, GAB2, FST, and MAP3K8 was relatively low, which might reflect the short duration of peak HBV DNA after the infection by BCP/PC or BCP/ PC/1938 mutant (Supporting Fig. S4A ). Microarray analysis showed that expression of glial cell-derived neurotrophic factor was modestly up-regulated in chimeric mice infected with BCP/PC/1938 mutant (Supporting Fig. S5 ), but the result was not confirmed by a validation analysis with real-time detection PCR.
We also found that levels of the fibrosis-related genes chemokine (C-X-C motif ) receptor 7 (CXCR7), endothelin 1 (EDN1), and insulin-like growth factor binding protein 3 (IGFBP3); the inflammation-related gene intercellular adhesion molecule 1 (ICAM1); and the HCC-related gene fibroblast growth factor 9 (FGF9) (30) (31) (32) (33) (34) increased in parallel with the levels of the five genes in the livers of mice with the BCP/ PC/2051 mutant (Supporting Fig. S10 and Table S1 ). These results suggest that HBV infection with genotype F1b, particularly the BCP/PC/2051 mutant, could significantly up-regulate the gene expression that has been associated with the HCC progression, fibrosis, and inflammation pathway.
Discussion
In this study, we identified an association between the Alaska-specific core mutations, T1938C and A2051C, and HCC development in AN people infected with genotype F1b (Table 1 and Figs. 1 and  2 ). Longitudinal sequencing analysis revealed that these core mutations had accumulated significantly with the HCC-associated BCP and PC mutations in HCC patients by the time of HCC diagnosis ( Table 1 ), suggesting that the accumulation of these core mutations in combination with BCP and PC mutations leads to HCC development. Interestingly, our in vitro examinations demonstrated that HBV clones containing the specific A2051C mutation, along with the amino acid change from asparagine to histidine at the core 51 position in the capsid assembly domain, strongly increased HBV replication in association with stabilized core protein dimerization ( Figs.  3 and 4; Supporting Fig. S3) . (35) We also showed that the HCC-associated mutant BCP/PC/2051 triggered inflammation and fibrosis in the human hepatocyte chimeric mouse model related to increased levels of genes that have been associated with HCC and/ or cell proliferation. These results suggest that the exceedingly high incidence of HCC among young AN people with accumulation of these mutations is attributable to the unique ability of genotype F1b to activate the factors that regulate cell proliferation and differentiation.
While genotype F was strongly associated with HCC development among AN people, (18) its virological basis has yet to be elucidated. In this study, we showed that core T1938C and A2051C mutations had accumulated significantly in the HCC patients. Especially the A2051C mutation, which strongly enhances replication efficiency, accumulated significantly close to HCC diagnosis ( (36, 37) these core mutations have been identified predominantly in Alaska (Supporting Fig. S2 ). Collectively, these results suggest that core T1938C and A2051C mutations contribute to the unique carcinogenic potential of genotype F1b of Alaska. In addition to the core mutations, BCP and PC mutations accumulated by the time of HCC diagnosis. Although these mutations were implicated in HCC development with other genotypes, (9, 10) their importance in genotype F1b-associated HCC is far less clear. In a previous study, BCP mutations were shown to occur more frequently in genotypes A2, B6, C, and D in this population than genotype F1b many years prior to HCC development. (18) It is also important to note that BCP and PC mutations had less impact on HBV replication than A2051C mutation in vitro (Fig. 3) . Therefore, BCP and PC mutations may be an innocent bystander to the core mutations that were specifically associated with genotype F1b in Alaska. Long-term follow-up studies with large Alaskan cohorts are needed to confirm the association between core mutations of genotype F1b and HCC development.
The HCC-associated BCP/PC/2051 mutations appeared to enhance the carcinogenic potential of genotype F1b. The BCP/PC/2051 mutant caused fibrosis and inflammation in the liver of human hepatocyte chimeric mouse ( Fig. 7A; Supporting Fig. S8 ), while the wild-type strain and BCP/PC and BCP/ PC/1938 mutants did not (Supporting Fig. S9A ). It is noteworthy that the BCP/PC/2051 mutant significantly enhanced HCC and/or proliferation-related gene expression (MYC, GAB2, BDKRB2, FST, and MAP3K8) in the chimeric mice compared to F wildtype strain (Supporting Table S4 ). The hepatitis B x protein transactivates the MYC gene, contributing to HCC in vitro and in vivo. (38, 39) Furthermore, studies have reported that the GAB2, BDKRB2, MAP3K8, and FST genes, which play roles in proliferation, survival, migration, and differentiation, were associated with the process of cancer development. (40) (41) (42) (43) (44) In addition, the BCP/PC/1938 mutant significantly up-regulated expression of the BDKRB2 gene as well as the BCP/PC/2051 mutant (Supporting Fig.  S9B ). Interestingly, fibrosis and inflammation induced by BCP/PC/2051 mutant infection (Fig. 7A) were associated with activation of inflammation-related ICAM1 as well as activation of fibrosis-related CXCR7, EDN1, and IGFBP3 (Supporting Table S1 ). These genes may up-regulate the HCC-associated genes MYC, GAB2, BDKRB2, MAP3K8, and FST (Supporting Fig. S8 and Tables S1 and S4). Based on these findings, it is possible that the BCP/PC/2051 mutant would contribute to tumor development by inducing inflammation and fibrosis-related gene expression. Unfortunately, however, the short life span of the chimeric mice prevented us from testing this hypothesis.
There are some limitations in this study. Firstly, although BCP/PC/2051 infection in chimeric mice caused inflammation and fibrosis, the mice did not develop HCC. This could be due to the limited duration of the experiment or the absence of immune response. Because the HBV-specific immune response was shown to cause HCC development, (45) another animal model with an intact immune system should be used to study the impact of the core mutations on HCC development. Secondly, we were able to determine up-regulation of the expression of HCCassociated genes in the chimeric mice infected with BCP/PC/2051 mutant, but additional functional analyses would be required to elucidate their physiological importance. Finally, the BCP/PC/1938 mutant was also associated with HCC development among AN people infected with genotype F1b, but the experimental data so far have failed to illuminate the carcinogenic potential of the mutant except for the modest up-regulation of the BDKRB2 gene in chimeric mice. Further studies would be needed to clarify the significance of BCP/PC/1938 mutant in HCC development.
In conclusion, we have shown that the Alaskaspecific core mutations, T1938C and A2051C, are uniquely associated with HCC development among AN people infected with genotype F1b. The A2051C mutation increased the replication efficacy of the BCP/PC/2051 mutant, which appeared to have greater carcinogenic potential than the wild-type strain and BCP/PC mutant. Accumulation of these core mutations during the course of chronic infection with genotype F1b might contribute to HCC development in AN people.
